BACKGROUND Metronidazole (MTZ) is indicated in the prevention of infections during surgical procedures. However, some data have shown that metronidazole has carcinogenic potential. METHODS In the present work, we determined concentrations of metronidazole and its hydroxy metabolite (MTZOH) in colorectal cancer patients. MTZ and MTZOH were measured in tumor tissue and surrounding healthy tissu...

Bioavailability File: Metronidazole Summary Metronidazole is an antimicrobial nitroimidazole derivative, which was originally introduced to treat Trichomonas vaginalis but nowadays is used for the treatment of anaerobic and protozoal infections. Metronidazole is bactericidal through toxic metabolites, which cause deoxyribonucleic acid (DNA) strand breakage. It has a bioavailability of more than...

Diarrhoeal diseases caused by the intestinal parasites Giardia lamblia and Entamoeba histolytica constitute a major global health burden. Nitroimidazoles are first-line drugs for the treatment of giardiasis and amebiasis, with metronidazole 1 being the most commonly used drug worldwide. However, treatment failures in giardiasis occur in up to 20% of cases and development of resistance to metron...

Trichomoniasis is the most prevalent nonviral sexually transmitted infection in the United States and affects over 11% of women over the age of 40 [1]. Metronidazole and tinidazole are the only medications that are recommended by the Centers for Disease Control for the treatment of trichomoniasis1. Alternative therapies are not standardized and limited in efficacy [2]. Case reports suggest that...

BACKGROUND Therapy for Helicobacter pylori is generally empiric despite the fact that resistance to metronidazole and clarithromycin compromise therapeutic efficacy. The aim of this study was to aid clinicians in choosing a course of therapy for H pylori infection in the United States. METHODS The frequency of primary clarithromycin and metronidazole resistance among H pylori isolated from pa...

BACKGROUND Clostridium difficile infection (CDI) is a common complication of antibiotic therapy that is treated with antibiotics, contributing to ongoing disruption of the colonic microbiota and CDI recurrence. Two multinational trials were conducted to compare the efficacy of tolevamer, a nonantibiotic, toxin-binding polymer, with vancomycin and metronidazole. METHODS Patients with CDI were ...